Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of$ 0.67. This compares to loss of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.94%. A quarter ago, it was expected that this company would post a loss of$ 0.67 per share when it actually produced a loss of $0.67, delivering no surprise.Over the last four quarters, the company has surpass ...